Ablynx NV News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.02.18	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
02.02.18	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
29.01.18	MÄRKTE EUROPA/Aktien knapp behauptet - Anleihen verlieren stark (Dow Jones)
29.01.18	MÄRKTE EUROPA/Aktien behauptet - Anleihekurse stark unter Druck (Dow Jones)
29.01.18	Sanofi sticht Novo Nordisk mit Ablynx-Kaufgebot aus (Dow Jones) Der französische Pharmakonzern Sanofi hat mit einem Übernahmeangebot den Wettbewerber Novo Nordisk ausgestochen.» mehr
29.01.18	SANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLION (GlobeNewswire)
24.01.18	ABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICER (GlobeNewswire)
22.01.18	ABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDS (GlobeNewswire)
18.01.18	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
18.01.18	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
16.01.18	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
16.01.18	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
10.01.18	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
09.01.18	MÄRKTE EUROPA/Autos mit Conti-Rekorden auf Rally-Kurs (Dow Jones)
09.01.18	MÄRKTE EUROPA/Conti-Hausse treibt Autotitel (Dow Jones)
09.01.18	MÄRKTE EUROPA/Mit angezogener Handbremse weiter aufwärts (Dow Jones)
09.01.18	MÄRKTE EUROPA/Gut behauptet - Dynamik der Gewinnserie lässt nach (Dow Jones)
08.01.18	MÄRKTE EUROPA/Gewinnserie dauert an (Dow Jones)
08.01.18	ABLYNX ANNOUNCES BOARD CHANGES (GlobeNewswire)
08.01.18	MÄRKTE EUROPA/Gewinnserie dauert an (Dow Jones)
08.01.18	ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS (GlobeNewswire)
08.01.18	MÄRKTE EUROPA/Gewinne dank Hoffnung auf fortgesetztes Wachstum (Dow Jones)
08.01.18	MÄRKTE EUROPA/Aufwärtsschwung lässt etwas nach - Ablynx ausgesetzt (Dow Jones)
08.01.18	Novo Nordisk überzeugt Ablynx mit Milliarden-Gebot nicht (Dow Jones)
04.01.18	ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (GlobeNewswire)
27.12.17	NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION (GlobeNewswire)
21.12.17	ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB (GlobeNewswire)
12.12.17	ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP (GlobeNewswire)
07.12.17	ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION (GlobeNewswire)
29.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
21.11.17	RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP SELECTED FOR PRESENTATION IN THE LATE-BREAKING ABSTRACTS SESSION AT THE 2017 ASH ANNUAL MEETING (GlobeNewswire)
16.11.17	ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE (GlobeNewswire)
15.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
15.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
10.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
09.11.17	ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON AND PARIS (GlobeNewswire)
07.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
07.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
07.11.17	CORRECTION OF PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
03.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
03.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
03.11.17	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
30.10.17	ABLYNX CLOSES ON UNDERWRITERS' OPTION TO PURCHASE $30 MILLION OF ADDITIONAL SHARES IN THE U.S. INITIAL PUBLIC OFFERING (GlobeNewswire)
27.10.17	ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES (GlobeNewswire)
27.10.17	ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD (GlobeNewswire)
25.10.17	NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020 (GlobeNewswire)
25.10.17	SUSPENSION OF TRADING IN ABLYNX SHARES ON EURONEXT BRUSSELS (GlobeNewswire)
25.10.17	ABLYNX PRICES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES (GlobeNewswire)
23.10.17	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
17.10.17	ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ablynx NV

Aktien Top/Flop

Meistgelesene Nachrichten